Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:RDY NASDAQ:RLAY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$81.82$74.25$14.30▼$84.55$11.52B1.281.53 million shs3.86 million shsRDYDr. Reddy's Laboratories$13.32+0.2%$13.35$12.19▼$15.71$11.09B0.271.44 million shs1.90 million shsRLAYRelay Therapeutics$15.88$14.25$3.03▼$17.47$3.04B1.753.88 million shs10.74 million shsSMMTSummit Therapeutics$13.75$18.04$12.55▼$30.98$10.67B-1.326.95 million shs8.72 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+9.80%+6.07%+45.25%+423.82%RDYDr. Reddy's Laboratories0.00%+0.11%-2.17%-3.31%-12.29%RLAYRelay Therapeutics0.00%+7.22%+21.97%+60.24%+372.62%SMMTSummit Therapeutics0.00%-1.86%-23.14%-11.35%-31.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$81.82$74.25$14.30▼$84.55$11.52B1.281.53 million shs3.86 million shsRDYDr. Reddy's Laboratories$13.32+0.2%$13.35$12.19▼$15.71$11.09B0.271.44 million shs1.90 million shsRLAYRelay Therapeutics$15.88$14.25$3.03▼$17.47$3.04B1.753.88 million shs10.74 million shsSMMTSummit Therapeutics$13.75$18.04$12.55▼$30.98$10.67B-1.326.95 million shs8.72 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+9.80%+6.07%+45.25%+423.82%RDYDr. Reddy's Laboratories0.00%+0.11%-2.17%-3.31%-12.29%RLAYRelay Therapeutics0.00%+7.22%+21.97%+60.24%+372.62%SMMTSummit Therapeutics0.00%-1.86%-23.14%-11.35%-31.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.69Moderate Buy$86.365.55% UpsideRDYDr. Reddy's Laboratories 1.67ReduceN/AN/ARLAYRelay Therapeutics 3.00Buy$23.3046.73% UpsideSMMTSummit Therapeutics 2.47Hold$27.2398.00% UpsideCurrent Analyst Ratings BreakdownLatest RLAY, RDY, SMMT, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026ARWRArrowhead Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$61.00 ➝ $72.006/11/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)6/1/2026SMMTSummit Therapeutics KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/26/2026RLAYRelay Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $26.005/26/2026RLAYRelay Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $28.005/22/2026SMMTSummit Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/22/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/21/2026SMMTSummit Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderperform$7.705/21/2026SMMTSummit Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell5/20/2026ARWRArrowhead Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M13.89$0.12 per share685.26$3.64 per share22.48RDYDr. Reddy's Laboratories$3.58B3.11$0.85 per share15.69$4.86 per share2.74RLAYRelay Therapeutics$15.35M198.21N/AN/A$3.27 per share4.86SMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)RDYDr. Reddy's Laboratories$456M$0.5822.9620.491.8312.90%12.34%8.24%7/22/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest RLAY, RDY, SMMT, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 million5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.53%+6.96%12.07%N/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23RDYDr. Reddy's Laboratories0.031.801.34RLAYRelay TherapeuticsN/A22.1322.13SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%RDYDr. Reddy's Laboratories3.85%RLAYRelay Therapeutics96.98%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%RDYDr. Reddy's Laboratories2.00%RLAYRelay Therapeutics5.04%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableRDYDr. Reddy's Laboratories27,527834.65 million817.96 millionOptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableRLAY, RDY, SMMT, and ARWR HeadlinesRecent News About These CompaniesSummit Therapeutics PLC $SMMT Shares Bought by Baker BROS. Advisors LPJune 18 at 4:14 AM | marketbeat.comMahkam Zanganeh Acquires 3,810,000 Shares of Summit Therapeutics (NASDAQ:SMMT) StockJune 14, 2026 | americanbankingnews.comRobert Duggan Purchases 3,810,000 Shares of Summit Therapeutics (NASDAQ:SMMT) StockJune 14, 2026 | americanbankingnews.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Hold" by BrokeragesJune 14, 2026 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 3,810,000 SharesJune 13, 2026 | insidertrades.comSummit Therapeutics PLC $SMMT Shares Bought by Polymer Capital Management HK LTDJune 13, 2026 | marketbeat.comWhy is SMMT stock tumbling today?June 10, 2026 | msn.comNorges Bank Takes $24.03 Million Position in Summit Therapeutics PLC $SMMTJune 10, 2026 | marketbeat.comSummit Therapeutics Announces Proposed Public Offering of Common StockJune 9, 2026 | businesswire.comSummit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comTD Asset Management Inc Increases Stock Position in Summit Therapeutics PLC $SMMTJune 8, 2026 | marketbeat.comMizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform TechJune 7, 2026 | 247wallst.comThe Era of the One-Size-Fits-All Cancer Drug Is EndingJune 6, 2026 | wsj.comSummit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial DataJune 5, 2026 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) CFO Manmeet Singh Soni Buys 50,000 SharesJune 5, 2026 | insidertrades.comSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 4, 2026 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)June 4, 2026 | theglobeandmail.comAssessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileJune 4, 2026 | finance.yahoo.comAll You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to BuyJune 4, 2026 | zacks.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - SlideshowJune 3, 2026 | seekingalpha.comCantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical DevelopmentsJune 2, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLAY, RDY, SMMT, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$81.82 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$82.40 +0.58 (+0.71%) As of 06/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Dr. Reddy's Laboratories NYSE:RDY$13.32 +0.03 (+0.22%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$13.18 -0.14 (-1.07%) As of 06/18/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Relay Therapeutics NASDAQ:RLAY$15.88 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$16.21 +0.33 (+2.08%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Summit Therapeutics NASDAQ:SMMT$13.75 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$13.74 -0.01 (-0.04%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
